Transform Cancers into Manageable Conditions
Transform Cancers into Manageable Conditions
Load image
Background image
About Us
About Us
Company Overview
We are a global clinical-stage biopharmaceutical company focused on the development of innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. We have assembled a world-class management team, built our unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.
Clinical Pipeline
Clinical Pipeline
R&D Platform
R&D Platform
Global Talent
Global Talent
View More
Background image Background image
Competitive Pipeline
Leveraging collaborations and internal discoveries, we have built a robust pipeline with strong potentials, including 11 drug candidates in development. Currently, four of them are being investigated in clinical trials, which are Buparlisib (AN2025), Pelareorep (AN1004), an oral EP4 antagonist (AN0025) and oral small-molecule PD-L1 inhibitor (AN4005).
View More
Background image Background image
Background image Background image Development Platform Development Platform
Research and Development
Platform
Led by a world-class executive and core R&D team, we have built our unique immuno-oncology platforms. Our innovation team is well positioned to establish ourselves as a leading global presence in the oncology market.
View More
Media
2022-03-14
Adlai Nortye Announces Appointment of Dr. Victoria Demby as Senior Vice President of Global Regulatory Affairs
2022-02-16
Adlai Nortye Announces Publication of Preclinical Research of AN3025 (anti-hTNFR2)in Frontiers in Immunology
2022-01-26
Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibitor (AN4005) and Anti-hTNFR2 Antibody (AN3025)
2022-01-06
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors
2021-10-14
Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
2021-09-08
Adlai Nortye Announces First Patient Dosed in Phase Ia Clinical Trial of AN2025 and AN0025 in Combination with atezolizumab for Advanced Solid Tumors
2021-04-15
Adlai Nortye Announces First Patient Dosed in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
2021-04-13
Adlai Nortye Presents Early Pre-Clinical Data on its Anti-hTNFR2 (AN3025) Program at the AACR Annual Meeting 2021
2021-03-26
Adlai Nortye Congratulates Dr. Ronald M. Evans, Chair of Scientific Advisory Board, on Receipt of the 2021 Asan Award in Basic Medicine
2021-03-08
Adlai Nortye Announces Formation of its New Scientific Advisory Board
2019-09-30
Adlai Nortye Presents Encouraging Phase 1b Study Data of AN0025 at ESMO 2019
2019-03-22
Adlai Nortye Receives NMPA Approval for Pelareorep Phase III Clinical Trials
View More